147 A Prospective Phase II, Open-Label, Single-arm, Multicenter Study to Assess the Efficacy and Safety of SEG101 (Crizanlizumab) in Sickle Cell Disease Patients With Priapism (SPARTAN)
Burnett, A., El Rassi, F., Darbari, D., Paulose, J., Lainé, D., Purkayastha, D., Kato, G.Volume:
17
Journal:
The Journal of Sexual Medicine
DOI:
10.1016/j.jsxm.2019.11.092
Date:
January, 2020
File:
PDF, 280 KB
2020
File converter
More search results
More benefits 
